VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ The patient agrees to the study protocol and the   │ The patient agrees to the study protocol and the   │     100 │
│ schedule of clinical and echocardiographic follow- │ schedule of clinical and echocardiographic follow- │         │
│ up, and provides informed, written consent, as     │ up, and provides informed, written consent, as     │         │
│ approved by the appropriate Institutional Review   │ approved by the appropriate Institutional Review   │         │
│ Board/Ethical Committee of the respective clinical │ Board/Ethical Committee of the respective clinical │         │
│ site                                               │ site                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwillingness or inability to comply with the      │ Unwillingness or inability to comply with the      │     100 │
│ procedures described in this protocol              │ procedures described in this protocol              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planned cardiac surgery or planned major non-      │ Planned cardiac surgery or planned major non-      │     100 │
│ cardiac surgery within the study period            │ cardiac surgery within the study period            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Stroke or coronary revascularization in the past 6 │ Stroke or coronary revascularization in the past 6 │     100 │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant pulmonary disease           │ Clinically significant pulmonary disease           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Untreated hyperthyroidism, or hypothyroidism       │ Untreated hyperthyroidism, or hypothyroidism       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A diagnosis of cancer (other than superficial      │ A diagnosis of cancer (other than superficial      │     100 │
│ squamous or basal cell skin cancer) in the past 3  │ squamous or basal cell skin cancer) in the past 3  │         │
│ years or current treatment for the active cancer   │ years or current treatment for the active cancer   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female of child-bearing potential who do not use   │ Female of child-bearing potential who do not use   │     100 │
│ adequate contraception and women who are pregnant  │ adequate contraception and women who are pregnant  │         │
│ or breast-feeding                                  │ or breast-feeding                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any clinically significant abnormality identified  │ Any clinically significant abnormality identified  │     100 │
│ at the screening visit, physical examination,      │ at the screening visit, physical examination,      │         │
│ laboratory tests, or electrocardiogram which, in   │ laboratory tests, or electrocardiogram which, in   │         │
│ the judgment of the Investigator, would preclude   │ the judgment of the Investigator, would preclude   │         │
│ safe completion of the study                       │ safe completion of the study                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic disease or biliary tract obstruction, or   │ Hepatic disease or biliary tract obstruction, or   │     100 │
│ significant hepatic enzyme elevation (ALT or AST   │ significant hepatic enzyme elevation (ALT or AST > │         │
│ \> 3 times upper limit of normal)                  │ 3 times upper limit of normal)                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of intolerance to ARB or amlodipine        │ History of intolerance to ARB or amlodipine        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypertrophic or restrictive cardiomyopathy         │ Hypertrophic or restrictive cardiomyopathy         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Moderate or severe valvular disease                │ Moderate or severe valvular disease                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Constrictive pericarditis                          │ Constrictive pericarditis                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ LV ejection fraction \< 50%                        │ LV ejection fraction < 50%                         │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sitting systolic BP \< 100 mmHg                    │ Sitting systolic BP < 100 mmHg                     │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Controlled hypertension: systolic BP \< 150 and    │ Controlled hypertension: systolic BP < 150 and     │      99 │
│ diastolic BP \< 90 mmHg in persons aged 60 years   │ diastolic BP < 90 mmHg in persons aged 60 years or │         │
│ or older, systolic BP \< 140 and diastolic BP \<   │ older, systolic BP < 140 and diastolic BP < 90     │         │
│ 90 mmHg in persons 40 through 59 years according   │ mmHg in persons 40 through 59 years according to   │         │
│ to the JNC 8th guideline                           │ the JNC 8th guideline                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of diastolic dysfunction showing E/E' \>  │ Evidence of diastolic dysfunction showing E/E' >   │      99 │
│ 10                                                 │ 10                                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant renal disease manifested by serum      │ Significant renal disease manifested by serum      │      99 │
│ creatinine \> 2.5 mg/dL                            │ creatinine > 2.5 mg/dL                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Atrial fibrillation with a heart rate \> 120/min   │ Atrial fibrillation with a heart rate > 120/min    │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                       │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════╪═════════╡
│ Must have minimum age of 40 Years │ Moderate or severe valvular disease │      35 │
├───────────────────────────────────┼─────────────────────────────────────┼─────────┤
│ Must have maximum age of 80 Years │ Moderate or severe valvular disease │      38 │
╘═══════════════════════════════════╧═════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 93.86363636363636
OverAll Ratio: 95.93181818181819
